Treatment of inflammatory bowel disease (IBD)
Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract, which includes Crohn’s disease (CD) and ulcerative colitis (UC). These diseases have become important health problems. Medical therapy for IBD has advanced dramatically in the last decade with the intro...
Gespeichert in:
| Veröffentlicht in: | Pharmacological reports 2011-05, Vol.63 (3), p.629-642 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 642 |
|---|---|
| container_issue | 3 |
| container_start_page | 629 |
| container_title | Pharmacological reports |
| container_volume | 63 |
| creator | Pithadia, Anand B. Jain, Sunita |
| description | Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract, which includes Crohn’s disease (CD) and ulcerative colitis (UC). These diseases have become important health problems. Medical therapy for IBD has advanced dramatically in the last decade with the introduction of targeted biologic therapies, the optimization of older therapies, including drugs such as immunomodulators and 5-aminosalicylic acid (5-ASA), and a better understanding of the mucosal immune system and the genetics involved in the pathogenesis of IBD. The goal of IBD therapy is to induce and maintain remission. The current treatment paradigm involves a step-up approach, moving to aggressive, powerful therapies only when milder therapies with fewer potential side effects fail or when patients declare themselves to have an aggressive disease. This review focuses on the current treatments for inflammatory bowel disease. |
| doi_str_mv | 10.1016/S1734-1140(11)70575-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_885056103</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1734114011705758</els_id><sourcerecordid>885056103</sourcerecordid><originalsourceid>FETCH-LOGICAL-c554t-d690e499c802c8f25250f4b20929e6105aa829985d3a877e49f0b496e09e645e3</originalsourceid><addsrcrecordid>eNqFkE9PwyAYh4nRuDn9CJre3A5VoNDSk9H5b8kSD84zYfStYWnLhFazby9b565e4PA-vx8vD0KXBN8QTNLbd5IlLCaE4TEhkwzzjMfiCA0pzfOYp4Ido-EBGaAz71cYM0ITfooGlAie4YwNUbxwoNoamjayZWSaslJ1rVrrNtHS_kAVFcaD8hCNZw-Pk3N0UqrKw8X-HqGP56fF9DWev73MpvfzWHPO2rhIcwwsz7XAVIuScspxyZYU5zSHlGCulAhrCl4kSmRZQEu8ZHkKOIwZh2SErvvetbNfHfhW1sZrqCrVgO28FIJjHoqSQPKe1M5676CUa2dq5TaSYLkVJXei5NZCOOROlBQhd7V_oVvWUBxSf2YCkPaAD6PmE5xc2c414df_Nt_1QQiCvk0Iem2g0VAYB7qVhTX_NPwCfhaFVA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>885056103</pqid></control><display><type>article</type><title>Treatment of inflammatory bowel disease (IBD)</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><source>SpringerLink Journals - AutoHoldings</source><creator>Pithadia, Anand B. ; Jain, Sunita</creator><creatorcontrib>Pithadia, Anand B. ; Jain, Sunita</creatorcontrib><description>Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract, which includes Crohn’s disease (CD) and ulcerative colitis (UC). These diseases have become important health problems. Medical therapy for IBD has advanced dramatically in the last decade with the introduction of targeted biologic therapies, the optimization of older therapies, including drugs such as immunomodulators and 5-aminosalicylic acid (5-ASA), and a better understanding of the mucosal immune system and the genetics involved in the pathogenesis of IBD. The goal of IBD therapy is to induce and maintain remission. The current treatment paradigm involves a step-up approach, moving to aggressive, powerful therapies only when milder therapies with fewer potential side effects fail or when patients declare themselves to have an aggressive disease. This review focuses on the current treatments for inflammatory bowel disease.</description><identifier>ISSN: 1734-1140</identifier><identifier>EISSN: 2299-5684</identifier><identifier>DOI: 10.1016/S1734-1140(11)70575-8</identifier><identifier>PMID: 21857074</identifier><language>eng</language><publisher>Cham: Elsevier Urban & Partner Sp. z o.o</publisher><subject>5-aminosalicylates ; Animals ; Anti-Inflammatory Agents - adverse effects ; Anti-Inflammatory Agents - therapeutic use ; Colitis, Ulcerative - drug therapy ; Colitis, Ulcerative - physiopathology ; corticosteroids ; Crohn Disease - drug therapy ; Crohn Disease - physiopathology ; Drug Delivery Systems ; Drug Safety and Pharmacovigilance ; Glucocorticoids - adverse effects ; Glucocorticoids - therapeutic use ; Humans ; Immunologic Factors - adverse effects ; Immunologic Factors - pharmacology ; Immunologic Factors - therapeutic use ; Immunosuppressive Agents - adverse effects ; Immunosuppressive Agents - therapeutic use ; inflammatory bowel disease (IBD) ; infliximab ; Pharmacotherapy ; Pharmacy ; Review</subject><ispartof>Pharmacological reports, 2011-05, Vol.63 (3), p.629-642</ispartof><rights>2011 Institute of Pharmacology Polish Academy of Sciences</rights><rights>Maj Institute of Pharmacology, Polish Academy of Sciences 2011</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c554t-d690e499c802c8f25250f4b20929e6105aa829985d3a877e49f0b496e09e645e3</citedby><cites>FETCH-LOGICAL-c554t-d690e499c802c8f25250f4b20929e6105aa829985d3a877e49f0b496e09e645e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1016/S1734-1140(11)70575-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1016/S1734-1140(11)70575-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21857074$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pithadia, Anand B.</creatorcontrib><creatorcontrib>Jain, Sunita</creatorcontrib><title>Treatment of inflammatory bowel disease (IBD)</title><title>Pharmacological reports</title><addtitle>Pharmacol. Rep</addtitle><addtitle>Pharmacol Rep</addtitle><description>Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract, which includes Crohn’s disease (CD) and ulcerative colitis (UC). These diseases have become important health problems. Medical therapy for IBD has advanced dramatically in the last decade with the introduction of targeted biologic therapies, the optimization of older therapies, including drugs such as immunomodulators and 5-aminosalicylic acid (5-ASA), and a better understanding of the mucosal immune system and the genetics involved in the pathogenesis of IBD. The goal of IBD therapy is to induce and maintain remission. The current treatment paradigm involves a step-up approach, moving to aggressive, powerful therapies only when milder therapies with fewer potential side effects fail or when patients declare themselves to have an aggressive disease. This review focuses on the current treatments for inflammatory bowel disease.</description><subject>5-aminosalicylates</subject><subject>Animals</subject><subject>Anti-Inflammatory Agents - adverse effects</subject><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Colitis, Ulcerative - drug therapy</subject><subject>Colitis, Ulcerative - physiopathology</subject><subject>corticosteroids</subject><subject>Crohn Disease - drug therapy</subject><subject>Crohn Disease - physiopathology</subject><subject>Drug Delivery Systems</subject><subject>Drug Safety and Pharmacovigilance</subject><subject>Glucocorticoids - adverse effects</subject><subject>Glucocorticoids - therapeutic use</subject><subject>Humans</subject><subject>Immunologic Factors - adverse effects</subject><subject>Immunologic Factors - pharmacology</subject><subject>Immunologic Factors - therapeutic use</subject><subject>Immunosuppressive Agents - adverse effects</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>inflammatory bowel disease (IBD)</subject><subject>infliximab</subject><subject>Pharmacotherapy</subject><subject>Pharmacy</subject><subject>Review</subject><issn>1734-1140</issn><issn>2299-5684</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE9PwyAYh4nRuDn9CJre3A5VoNDSk9H5b8kSD84zYfStYWnLhFazby9b565e4PA-vx8vD0KXBN8QTNLbd5IlLCaE4TEhkwzzjMfiCA0pzfOYp4Ido-EBGaAz71cYM0ITfooGlAie4YwNUbxwoNoamjayZWSaslJ1rVrrNtHS_kAVFcaD8hCNZw-Pk3N0UqrKw8X-HqGP56fF9DWev73MpvfzWHPO2rhIcwwsz7XAVIuScspxyZYU5zSHlGCulAhrCl4kSmRZQEu8ZHkKOIwZh2SErvvetbNfHfhW1sZrqCrVgO28FIJjHoqSQPKe1M5676CUa2dq5TaSYLkVJXei5NZCOOROlBQhd7V_oVvWUBxSf2YCkPaAD6PmE5xc2c414df_Nt_1QQiCvk0Iem2g0VAYB7qVhTX_NPwCfhaFVA</recordid><startdate>20110501</startdate><enddate>20110501</enddate><creator>Pithadia, Anand B.</creator><creator>Jain, Sunita</creator><general>Elsevier Urban & Partner Sp. z o.o</general><general>Springer International Publishing</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20110501</creationdate><title>Treatment of inflammatory bowel disease (IBD)</title><author>Pithadia, Anand B. ; Jain, Sunita</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c554t-d690e499c802c8f25250f4b20929e6105aa829985d3a877e49f0b496e09e645e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>5-aminosalicylates</topic><topic>Animals</topic><topic>Anti-Inflammatory Agents - adverse effects</topic><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Colitis, Ulcerative - drug therapy</topic><topic>Colitis, Ulcerative - physiopathology</topic><topic>corticosteroids</topic><topic>Crohn Disease - drug therapy</topic><topic>Crohn Disease - physiopathology</topic><topic>Drug Delivery Systems</topic><topic>Drug Safety and Pharmacovigilance</topic><topic>Glucocorticoids - adverse effects</topic><topic>Glucocorticoids - therapeutic use</topic><topic>Humans</topic><topic>Immunologic Factors - adverse effects</topic><topic>Immunologic Factors - pharmacology</topic><topic>Immunologic Factors - therapeutic use</topic><topic>Immunosuppressive Agents - adverse effects</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>inflammatory bowel disease (IBD)</topic><topic>infliximab</topic><topic>Pharmacotherapy</topic><topic>Pharmacy</topic><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pithadia, Anand B.</creatorcontrib><creatorcontrib>Jain, Sunita</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pharmacological reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pithadia, Anand B.</au><au>Jain, Sunita</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of inflammatory bowel disease (IBD)</atitle><jtitle>Pharmacological reports</jtitle><stitle>Pharmacol. Rep</stitle><addtitle>Pharmacol Rep</addtitle><date>2011-05-01</date><risdate>2011</risdate><volume>63</volume><issue>3</issue><spage>629</spage><epage>642</epage><pages>629-642</pages><issn>1734-1140</issn><eissn>2299-5684</eissn><abstract>Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract, which includes Crohn’s disease (CD) and ulcerative colitis (UC). These diseases have become important health problems. Medical therapy for IBD has advanced dramatically in the last decade with the introduction of targeted biologic therapies, the optimization of older therapies, including drugs such as immunomodulators and 5-aminosalicylic acid (5-ASA), and a better understanding of the mucosal immune system and the genetics involved in the pathogenesis of IBD. The goal of IBD therapy is to induce and maintain remission. The current treatment paradigm involves a step-up approach, moving to aggressive, powerful therapies only when milder therapies with fewer potential side effects fail or when patients declare themselves to have an aggressive disease. This review focuses on the current treatments for inflammatory bowel disease.</abstract><cop>Cham</cop><pub>Elsevier Urban & Partner Sp. z o.o</pub><pmid>21857074</pmid><doi>10.1016/S1734-1140(11)70575-8</doi><tpages>14</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1734-1140 |
| ispartof | Pharmacological reports, 2011-05, Vol.63 (3), p.629-642 |
| issn | 1734-1140 2299-5684 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_885056103 |
| source | MEDLINE; Alma/SFX Local Collection; SpringerLink Journals - AutoHoldings |
| subjects | 5-aminosalicylates Animals Anti-Inflammatory Agents - adverse effects Anti-Inflammatory Agents - therapeutic use Colitis, Ulcerative - drug therapy Colitis, Ulcerative - physiopathology corticosteroids Crohn Disease - drug therapy Crohn Disease - physiopathology Drug Delivery Systems Drug Safety and Pharmacovigilance Glucocorticoids - adverse effects Glucocorticoids - therapeutic use Humans Immunologic Factors - adverse effects Immunologic Factors - pharmacology Immunologic Factors - therapeutic use Immunosuppressive Agents - adverse effects Immunosuppressive Agents - therapeutic use inflammatory bowel disease (IBD) infliximab Pharmacotherapy Pharmacy Review |
| title | Treatment of inflammatory bowel disease (IBD) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T21%3A24%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20inflammatory%20bowel%20disease%20(IBD)&rft.jtitle=Pharmacological%20reports&rft.au=Pithadia,%20Anand%20B.&rft.date=2011-05-01&rft.volume=63&rft.issue=3&rft.spage=629&rft.epage=642&rft.pages=629-642&rft.issn=1734-1140&rft.eissn=2299-5684&rft_id=info:doi/10.1016/S1734-1140(11)70575-8&rft_dat=%3Cproquest_cross%3E885056103%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=885056103&rft_id=info:pmid/21857074&rft_els_id=S1734114011705758&rfr_iscdi=true |